baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Akari Therapeutics PLC/ US00972G2075 /

2024-04-24 8:50:06 PM	Chg. -0.0200	Volume	Bid12:00:00 AM	Ask12:00:00 AM	High	Low
1.1900USD	-1.65%	7,532 Turnover: 7,958.0731	1.1100Bid Size: 100	1.2000Ask Size: 200	1.2100	1.1701

GlobeNewswire 04-15 Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

GlobeNewswire 04-01 Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

GlobeNewswire 03-15 SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger – SDPI, MINM, SCX, AKTX

GlobeNewswire 03-15 SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX

GlobeNewswire 03-09 INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK

GlobeNewswire 03-08 Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm

GlobeNewswire 03-05 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expande...

GlobeNewswire 01-02 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Pla...

GlobeNewswire 2023-12-14 Akari Therapeutics to Present at Biotech Showcase 2024

GlobeNewswire 2023-12-01 Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of ...

GlobeNewswire 2023-11-16 Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomaco...

GlobeNewswire 2023-11-06 Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a...

GlobeNewswire 2023-10-04 Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now

GlobeNewswire 2023-10-03 Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

GlobeNewswire 2023-09-29 Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

GlobeNewswire 2023-09-27 Akari Therapeutics to Present at Emerging Growth Conference

GlobeNewswire 2023-09-21 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Pla...

GlobeNewswire 2023-09-19 Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related ...

GlobeNewswire 2023-09-05 Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire 2023-08-18 Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding O...

GlobeNewswire 2023-08-15 Akari Therapeutics, Plc Announces ADS Ratio Change

GlobeNewswire 2022-03-21 Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and ...

GlobeNewswire 2022-03-08 Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

GlobeNewswire 2022-03-02 Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Akari Therapeutics PLC/ US00972G2075 /

If you wish to receive reply to your feedback, please provide your email address.